{"schema_version":"secwatch.filing_event.v1","accession":"0001625297-25-000021","form_type":"8-K","ticker":"INDV","cik":"0001625297","company_name":"Indivior Pharmaceuticals, Inc.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.229060+00:00","generated_at":"2026-05-25T14:05:07.567252+00:00","sec_items":["1.01","5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"confidence":"high","headline":"Indivior appoints Joe Ciaffoni as CEO, reduces board to 7, enters amended Oaktree deal","bullets":["Joe Ciaffoni appointed CEO effective after 2025 AGM but no later than Aug 1, 2025; Mark Crossley remains CEO until then.","Ciaffoni gets base salary $1,050,000, bonus target 100% of salary, max 200%; on-hire PSUs worth 12x salary (up to 1.575M shares) and RSUs 4x salary (up to 525K shares).","Board reduced to 7 directors at 2025 AGM; Peter Bains and Jo LeCouilliard not standing for re-election; Robert Schriesheim resigned effective March 2.","Amended relationship with Oaktree: board to be 8 after search for one new independent director by July 1; Daniel Ninivaggi chairs Nomination Committee.","Barbara Ryan to succeed Jo LeCouilliard as Chair of Compensation Committee after the 2025 AGM."],"urls":{"canonical":"https://secwatch.observer/filing/0001625297-25-000021","json":"https://secwatch.observer/filing/0001625297-25-000021.json","markdown":"https://secwatch.observer/filing/0001625297-25-000021.md","text":"https://secwatch.observer/filing/0001625297-25-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000021/0001625297-25-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000021/indv-20250302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T14:05:07.567252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6d26978c1d","claim":"Jo LeCouilliard departed as Non-Executive Director at Indivior Pharmaceuticals, Inc..","evidence_excerpt":"Peter Bains and Jo LeCouilliard have decided not to stand for re-election at the Company’s Annual General Meeting.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000021/0001625297-25-000021-index.htm","confidence":0.9},{"claim_id":"7191bb2048","claim":"Joe Ciaffoni was appointed as Chief Executive Officer at Indivior Pharmaceuticals, Inc..","evidence_excerpt":"the announcement on February 27, 2025 of the appointment of Joe Ciaffoni as Chief Executive Officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000021/0001625297-25-000021-index.htm","confidence":0.95},{"claim_id":"cab463b328","claim":"Peter Bains departed as Non-Executive Director at Indivior Pharmaceuticals, Inc..","evidence_excerpt":"Peter Bains and Jo LeCouilliard have decided not to stand for re-election at the Company’s Annual General Meeting.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000021/0001625297-25-000021-index.htm","confidence":0.9},{"claim_id":"cd4cd6aa25","claim":"Robert Schriesheim resigned as Independent Non-Executive Director at Indivior Pharmaceuticals, Inc..","evidence_excerpt":"Robert Schriesheim notified the Board of his resignation therefrom on March 2, 2025 with immediate effect.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000021/0001625297-25-000021-index.htm","confidence":0.95}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}